Aprea Therapeutics, Inc. — fact timeline

Aprea Therapeutics, Inc. shareholders approved A proposal to approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,056,154 191,486 20,811 0”

Aprea Therapeutics, Inc. shareholders approved A proposal to approve, by non-binding advisory vote, the frequency of future votes on the compensation of the Company’s named executive officers. at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve, by non-binding advisory vote, the frequency of future votes on the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: 1 Year 2 Years 3 Years Votes Abstaining 4,276,181 22,984 1,056,208 526,693”

Aprea Therapeutics, Inc. shareholders approved A proposal to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 5,777,837 78,853 25,376 2,386,385”

Aprea Therapeutics, Inc. shareholders approved A proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, and to authorize the Board of Directors of the Company (the “Board”) to effect a reverse stock split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a ratio of not at the 2026-06-16 meeting.

“The Company’s stockholders voted to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, and authorized the Board to effect a reverse stock split of the Common Stock at a ratio of not less than one-for-three and not more than one-for-eight of the Common Stock (with all fractional shares rounded up to the nearest whole share) (the “Reverse Stock Split”), with the exact ratio to be set within this range by the Board in its sole discretion (without reducing the authorized number of shares of the Common Stock), and with the Reverse Stock Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion (“Proposal 3”). The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,038,052 210,751 19,648 0”

Aprea Therapeutics, Inc. shareholders approved A proposal to ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year. at the 2026-06-16 meeting.

“The Company’s stockholders ratified the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year 2026. The votes regarding this proposal were as follows: Votes For Votes Against Votes Abstaining Broker Non-Votes 8,107,969 44,299 116,183 0”

Aprea Therapeutics, Inc. shareholders approved A proposal to elect three Class I directors of the Company, Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D., each to hold office until the 2029 Annual Meeting of Stockholders or until their respective successors shall have been duly elected and qualified. at the 2026-06-16 meeting.

“The Company’s stockholders elected the following directors to serve as Class I directors until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Marc Duey 5,817,488 64,578 2,386,385 Richard Peters, M.D. 5,824,115 57,951 2,386,385 Bernd R. Seizinger, M.D., Ph.D. 5,495,110 386,956 2,386,385”

Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.

“On May 13, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026, and provided an update on the Company’s operations for the same period.”

Aprea Therapeutics, Inc. issued Pre-Funded Warrant Shares of common stock to certain accredited investors for expected gross proceeds of the Private Placement are approximately $30 million.

“occur on March 31, 2026, subject to satisfaction of customary closing conditions (the “ Closing Date ”). The expected gross proceeds of the Private Placement are approximately $30 million, before deducting the placement agent fees and estimated offering expenses payable by the Company. The Common Warrants will be exercisable immediately until December 31, 2029”

Aprea Therapeutics, Inc. issued up to approximately 37.2 million shares of warrant to certain accredited investors for purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price.

“shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares”

Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at Gross proceeds of approximately $30 million (effective 2026-03-30).

“On March 30, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) to purchase up to approximately 37.2 million shares (the “ Pre-Funded Warrant Shares ”) of common stock, par value $0.001 per share of the Company (“ Common Stock ”) at a purchase price per Pre-Funded Warrant equal to $0.808, less the Pre-Funded Warrant Exercise Price, and (ii) common stock purchase warrants to purchase up to approximately 37.2 million shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.683 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”).”

Aprea Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

“On March 16, 2026, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2025”

Aprea Therapeutics, Inc. issued up to 6,288,857 shares of Common Stock of warrant to certain accredited investors for $0.89 per unit (combined with share or warrant).

“Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $5.6 million. The closing of”

Aprea Therapeutics, Inc. issued warrant to certain accredited investors for $0.89 per unit (combined with share or warrant).

“Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $5.6 million. The closing of”

Aprea Therapeutics, Inc. issued 6,288,857 shares of common stock to certain accredited investors for $0.89 per unit (combined with warrant).

“Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $5.6 million. The closing of”

Aprea Therapeutics, Inc. entered into Registration Rights Agreement with the Company and the Purchasers valued at customary indemnification rights (effective 2026-01-29).

“In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated January 29, 2026 (the “ Registration Rights Agreement ”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “ Registration Statement ”) to be filed with the Securities and Exchange Commission (the “ SEC ”) on or prior to the 60 th day after the Closing Date.”

Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain accredited investors (the Purchasers) valued at expected aggregate gross proceeds at closing of approximately $5.6 million (effective 2026-01-28).

“On January 28, 2026, Aprea Therapeutics, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 6,288,857 shares (the “ Private Placement Shares ”) of the Company’s Common Stock, par value $0.001 per share (“ Common Stock ”) or pre-funded Common Stock purchase warrants (the “ Pre-Funded Warrants ”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 6,288,857 shares of Common Stock (the “ Warrant Shares ”) at an exercise price of $0.765 per share (the “ Common Warrants ” and together with the Pre-Funded Warrants, the “ Warrants ”). The combined effective offering price of each Private Placement Share or Pre-Funded Warrant and accompanying Common Warrant to be issued is $0.89 and represents the “ Minimum Price ” in accordance with Nasdaq”

Aprea Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“January 23, 2026, Aprea Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock”

Aprea Therapeutics, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2025-12-08).

“On December 8, 2025, and in connection with the Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”).”

Aprea Therapeutics, Inc. entered into Registration Rights Agreement with the Purchasers (effective 2025-12-08).

“In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated December 8, 2025 (the “Registration Rights Agreement”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants, and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) on or prior to the 20 th day after the Closing Date.”

Aprea Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors and Company insiders valued at approximately $3.1 million (effective 2025-12-08).

“On December 8, 2025, Aprea Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors and Company insiders (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 2,623,023 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.001 per share (“Common Stock”) or pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 2,623,023 shares of Common Stock (the “Warrant Shares”) at an exercise price of $1.04 per share (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”).”

Aprea Therapeutics, Inc. issued 2,623,023 shares of common stock to accredited investors and Company insiders for combined effective offering price of $1.165 per share, expected aggregate gross proceeds at closing of approximately $3.1 million.

“and together with the Pre-Funded Warrants, the “Warrants”). The combined effective offering price of each Private Placement Share and accompanying Common Warrant to be issued is $1.165 and represents the “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $3.1 million. The closing of”

Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.

“On May 14, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024, and provided an update on the Company’s operations for the same period.”

Aprea Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds of approximately $16.0 million (effective 2024-03-11).

“On March 11, 2024, Aprea Therapeutics, Inc. (the "Company") entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain investors (the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 1,687,712 shares (the "Private Placement Shares") of the Company’s Common Stock, par value $0.001 per share ("Common Stock") at a purchase price of $7.29 per share, (ii) pre-funded Common Stock purchase warrants (the "Pre-Funded Warrants") to purchase an aggregate of up to 507,076 shares of Common Stock at an exercise price of $0.001 per share, (iii) Tranche A Common Stock purchase warrants to purchase up to 1,097,394 shares of Common Stock at an exercise price of $7.29 per share (the "Tranche A Warrants"), and (iv) Tranche B Common Stock purchase warrants to purchase up to 1,097,394 shares of Common Stock at an exercise price of $9.1125 per share (the "Tranche B Warrants"”

Aprea Therapeutics, Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at up to $1.0 million (effective 2024-01-26).

“On January 26, 2024, Aprea Therapeutics, Inc. (the “Company”) entered into an at the market offering agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “HCW”).”

Aprea Therapeutics, Inc. reported three and nine months ended September 30, 2023 results: net income a net loss of $3.2 million ($0.86 per basic share), EPS ($0.86 per basic share).

“Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update”

Jean-Pierre Bizzari was appointed as Class III Director at Aprea Therapeutics, Inc..

“Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Dr. Jean-Pierre Bizzari as a Class III director, effective immediately”

Richard Peters was appointed as Chairperson of the Board at Aprea Therapeutics, Inc..

“Following Mr. Schade’s resignation, on August 23, 2023, the Board appointed Richard Peters, M.D., Ph.D., to serve as Chairperson of the Board, effective immediately.”

Christian S. Schade resigned as Chairperson of the Board and Director at Aprea Therapeutics, Inc..

“On August 23, 2023, Christian S. Schade resigned from the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”), including as Chairperson of the Board and any respective committee of the Board to which he was a member, effective immediately.”

Aprea Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $3.3 million, EPS $0.87 per basic share.

“The Company reported a net loss of $3.3 million ($0.87 per basic share) on approximately 3.7 million weighted-average common shares outstanding for the quarter ended June 30, 2023”

Aprea Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income net loss of $4.4 million, EPS $1.34 per basic share.

“The Company reported a net loss of $4.4 million ($1.34 per basic share) on approximately 3.3 million weighted-average common shares outstanding for the quarter ended March 31, 2023”

Gabriela Gruia, M.D. was appointed as Class II director at Aprea Therapeutics, Inc..

“On May 5, 2023, the Board of Directors (the “Board”) of Aprea Therapeutics, Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Gabriela Gruia, M.D., as a Class II director and new member of the Board to fill the vacancy on the Board, effective immediately, to serve until the Company’s 2024 annual meeting of stockholders or until her earlier resignation or removal.”

Aprea Therapeutics, Inc. engaged EisnerAmper LLP as its auditor.

“On April 17, 2023, in connection with the Company’s dismissal of EY, the Company engaged EisnerAmper LLP (“EisnerAmper”) as its new independent registered public accounting firm to audit the Company’s financial statements for the year ending December 31, 2023.”

Aprea Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.

“On April 17, 2023, Aprea Therapeutics, Inc. (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm.”

Aprea Therapeutics, Inc. entered into Underwriting Agreement with Maxim Group LLC valued at approximately $4.8 million (effective 2023-02-22).

“On February 22, 2023, Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC as representative of the underwriters named therein (the “Underwriters”) relating to the issuance and sale of 1,050,000 shares of the Company’s common stock, par value $0.001 per share (the “Offering”).”

Aprea Therapeutics, Inc.: Amended Certificate of Incorporation to effect a one-for-20 reverse stock split (effective 2023-02-10).

“the Company filed an amendment to its Certificate of Incorporation (the ‘Amendment”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, with an effective time of 5:00 p.m. on February 10, 2023.”

Scott Coiante departed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..

“Mr. Hamill will replace Scott Coiante, who will step down from his role as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective as of the Transition Date.”

John Hamill was appointed as Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer at Aprea Therapeutics, Inc..

“Effective January 30, 2023 (the “Transition Date”), John Hamill became Senior Vice President, Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer of Aprea Therapeutics, Inc.”

Aprea Therapeutics, Inc. shareholders approved Approval of adjournment of the Special Meeting to solicit additional proxies if necessary at the 2022-11-16 meeting.

“Proposal 2: Stockholders approved the adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes to adopt the Reverse Stock Split Proposal. Votes For Votes Against Abstentions Broker Non-Votes 36,441,099 1,892,580 565,864 —”

Aprea Therapeutics, Inc. shareholders approved Approval of reverse stock split at a ratio between 1-for-3 and 1-for-20 inclusive at the 2022-11-16 meeting.

“Proposal 1: Stockholders approved the amendments to the Company’s Certificate of Incorporation, to effect a reverse stock split at a ratio of 1-for-3 and 1-for-20, inclusive, with the exact ratio to be set within that range at the discretion of the Company’s Board of Directors before February 28, 2023 without further approval or authorization of our stockholders and with our Board of Directors able to elect to abandon such proposed amendment and not effect the Reverse Stock Split authorized by stockholders, in its sole discretion. Votes For Votes Against Abstentions Broker Non-Votes 36,030,837 2,418,669 450,037 —”

Aprea Therapeutics, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5450(b)(1)(A)).

“set forth in Listing Rule 5450(b)(1)(A) (the “Rule”). Based on the Company’s Form 10-Q for the period ended September 30, 2022, evidencing stockholders’ equity of approximately $26.6 million, the Staff has determined that the Company has regained compliance with the Rule. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant”

Aprea Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $4.0 million, or $0.12 per share, EPS $0.12 per share.

“Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and nine months ended September 30, 2022 and provided a business update.”

Marc Duey was appointed as Director at Aprea Therapeutics, Inc..

“Marc Duey was appointed as a Class I director”

Rif Pamukcu was appointed as Director at Aprea Therapeutics, Inc..

“Michael Grissinger and Rif Pamukcu were appointed as Class II directors.”

Michael Grissinger was appointed as Director at Aprea Therapeutics, Inc..

“Michael Grissinger and Rif Pamukcu were appointed as Class II directors.”

Michael A. Kelly resigned as Director at Aprea Therapeutics, Inc..

“Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.”

Fouad Namouni resigned as Director at Aprea Therapeutics, Inc..

“Fouad Namouni and Michael A. Kelly resigned from the Board as Class II and Class III directors, respectively, and any respective committee of the Board to which they were members, effective at the Second Effective Time.”

Oren Gilad was appointed as Director at Aprea Therapeutics, Inc..

“Dr. Gilad was appointed as a Class III director”

Oren Gilad was appointed as Chief Executive Officer at Aprea Therapeutics, Inc..

“Effective as of the conclusion of the Stockholders’ Meeting, Dr. Gilad will be appointed to the position of Chief Executive Officer of Aprea, to fill the vacancy created by Christian S. Schade’s resignation as Chief Executive Officer of Aprea”

Oren Gilad was appointed as President at Aprea Therapeutics, Inc..

“the appointment of Oren Gilad, Ph.D. to the position of the President of Aprea”

Christian S. Schade resigned as Chief Executive Officer at Aprea Therapeutics, Inc..

“Effective as of the conclusion of the Stockholders’ Meeting, Christian S. Schade will resign as Chief Executive Officer.”